Page last updated: 2024-08-17

levodopa and cabergoline

levodopa has been researched along with cabergoline in 73 studies

Research

Studies (73)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	17 (23.29)	18.2507
2000's	39 (53.42)	29.6817
2010's	15 (20.55)	24.3611
2020's	2 (2.74)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Lera, G; Muruzabal, J; Obeso, JA; Vaamonde, J	1
Mark, MH; Sage, JI	1
Lera, G; Obeso, JA; Rodriguez, M; Vaamonde, J	1
Ahlskog, JE; Imke, S; Lieberman, A; Maraganore, DM; Matsumoto, JY; Muenter, M; Schoenfelder, J; Wheeler, K; Wright, KF	1
Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ	1
Adler, CH; Ahlskog, JE; Muenter, MD; Wright, KF	1
Bonuccelli, U; Colzi, A; Del Dotto, P; Dubini, A; Grimaldi, R; Lucetti, C; Pardini, C	1
Adler, CH; Ahlskog, JE; Hiner, BC; Hurtig, HI; Hutton, JT; Koller, WC; Lieberman, A; Morris, JL; Muenter, MD; Pahwa, R; Pfeiffer, RF; Rodnitzky, RL; Stern, MB; Waters, CH	1
Anderson, T; El-Debas, T; Findley, LJ; Marsden, CD; Steiger, MJ	1
Arai, N; Isaji, M; Itoh, F; Kojima, M; Komatsu, Y; Miyagi, M; Taya, F	1
Arai, N; Isaji, M; Kojima, M; Kuno, S; Mizuta, E	1
Bracco, F; Chouza, C; Dubini, A; Dupont, E; Gershanik, O; Grimaldi, R; Marsden, CD; Marti Masso, JF; Montastruc, JL; Orlando, N; Rinne, UK	1
Bonuccelli, U; Colzi, A; Del Dotto, P; Fariello, R; Musatti, E; Persiani, S; Strolin Benedetti, M	1
Fariello, RG	1
Marsden, CD	1
Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marsden, CD; Marti Masso, JF; Montastruc, JL; Rinne, UK	1
Montastruc, JL; Rascol, O; Senard, JM	1
LeWitt, PA	1
Agapito, C; Bhattacharya, KF; Chaudhuri, KR; Pal, S	1
Clarke, CE; Deane, KH	1
Clarke, CE; Deane, KD	1
Ichikawa, K; Kojima, M	1
Abe, K; Kashihara, K; Manabe, Y; Murakami, T	1
Brunner, H; Friess, E; Hogl, B; Trenkwalder, C; Wetter, TC; Yassouridis, A	1
Clarke, CE; Guttman, M	1
Berardelli, A; De Pandis, MF; Modugno, N; Ruggieri, S; Stocchi, F; Thomas, A; Vacca, L; Valente, M	1
Abe, K; Hotta, K; Igarashi, K; Kasuya, F; Sakoda, S	1
Kodama, R; Kondo, T; Miwa, H; Morita, S	1
Bonuccelli, U; Del Dotto, P	1
Berger, KB; Dodel, RC; DuChane, J; Köhne-Volland, R; Machat, O; Meyer, D; Oertel, WH; Reuther, M; Siebert, U; Smala, AM; Spottke, EA	1
Inzelberg, R; Nisipeanu, P; Schechtman, E	1
Harada, H; Hashimoto, H; Kono, I; Nakagawa, M; Yoshida, T; Yoshikawa, K	1
Burkhard, PR; Flachsbart, KD; Fross, RD; Horvath, J; Kleiner-Fisman, G; Lang, AE; Lerch, R; Liaudat, S; Pache, JC; Rakowski, H; Raskoff, WJ; Stalder, H	1
Clarke, CE; Gray, R; Ives, N; Wheatley, K	1
Marras, C	1
Battaglia, A; Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marti Masso, JF; Montastruc, JL	1
Grosset, D; Grosset, K; Macphee, G; Needleman, F	1
Ogawa, N; Tanaka, K	1
Ling, W; Majewska, MD; Montgomery, MA; Rawson, RA; Reiber, C; Shoptaw, S; Watson, DW	1
Goetz, CG; Poewe, W; Rascol, O; Sampaio, C	1
Comella, C; Widnell, KL	1
Arthur, K; Foley, SR; Kelly, BD	1
Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G	1
Abe, T; Isobe, C; Kikuchi, T; Murata, T; Sato, C; Terayama, Y	1
Brusa, L; Cervellino, A; Giacomini, P; Grossi, K; Izzi, F; Marciani, MG; Pierantozzi, M; Placidi, F; Romigi, A; Stanzione, P	1
Kanzato, N; Murao, H; Nishihira, T; Takara, H	1
Benes, H; Grote, L; Happe, S; Högl, B; Kohnen, R; Mathis, J; Saletu-Zyhlarz, GM; Trenkwalder, C	1
Benes, H; Högl, B; Kohnen, R; Trenkwalder, C	1
Adeva-Bartolomé, T; Alonso-Navarro, H; Jiménez-Jiménez, FJ; Ruiz-Ezquerro, JJ	1
Bédard, PJ; Bélanger, N; Calon, F; Di Paolo, T; Dridi, M; Grégoire, L; Hadj Tahar, A; Morissette, M; Samadi, P	1
Dengler, R; Joppich, G; Möbes, J; Schröder, C; Stiebritz, F	1
Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR	1
Belkhir, S; Di Paolo, T; Dridi, M; Grégoire, L; Meltzer, LT; Morissette, M; Ouattara, B; Samadi, P	1
Arai, H; Hatta, K; Hattori, N; Ishikawa, K; Kamigaichi, R; Kubo, S; Mochizuki, H; Ogaki, K; Usui, C; Yokoyama, K	1
Kulisevsky, J; Martinez-Corral, M; Pagonabarraga, J	1
Bélanger, N; Di Paolo, T; Hadj Tahar, A; Morissette, M; Samadi, P	1
Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hoyer, D; Morissette, M; Ouattara, B	1
Hornyak, M; Kohnen, R; Kriston, L; Riemann, D; Scholz, H; Trenkwalder, C	1
Di Paolo, T; Morissette, M; Parent, M; Riahi, G	1
Brioschi, A; Mauro, A; Pignatti, R; Semenza, C; Wenter, J; Zamarian, L	1
Utsumi, H	1
Bini, V; Bortolato, M; Cannas, A; Marrosu, F; Puligheddu, M; Solla, P	1
George, S; Jones, HB	1
Aurora, RN; Bista, SR; Casey, KR; Kristo, DA; Lamm, CI; Rosenberg, RS; Rowley, JA; Tracy, SL; Zak, RS	1
Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H	1
Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ	1
Beuthien-Baumann, B; Grählert, X; Herting, B; Kotzerke, J; Löhle, M; Oehme, L; Perick, M; Reichmann, H; Schwanebeck, U; Storch, A; van den Hoff, J; Wolz, M	1
Hisanaga, R; Nakamura, M; Nomoto, S; Sato, T	1
Ikeda, S; Ishizaki, T; Nakaoka, S; Nakayama, T; Satoh, T; Urushihara, H; Yamamoto, M	1
Kimura, T; Kinoshita, I; Kon, T; Miki, Y; Mori, F; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M; Wakabayashi, K	1
Chang, TM; Chen, HA; Chien, YH; Hsu, RH; Hwu, WL; Lee, NC	1

Reviews

17 review(s) available for levodopa and cabergoline

Article	Year
Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Drugs, 1998, Volume: 55 Suppl 1 Topics: Animals; Antiparkinson Agents; Area Under Curve; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2	1998
Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Drugs, 1998, Volume: 55 Suppl 1 Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic	1998
Treatment of Parkinson's disease should begin with a dopamine agonist. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:5 Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles	1999
New drugs for the treatment of Parkinson's disease. Pharmacotherapy, 2000, Volume: 20, Issue:1 Pt 2 Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Synergism; Enzyme Inhibitors; Ergolines; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone	2000
Cabergoline for levodopa-induced complications in Parkinson's disease. The Cochrane database of systematic reviews, 2001, Issue:1 Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic	2001
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. The Cochrane database of systematic reviews, 2001, Issue:1 Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic	2001
[Pharmacological effects of cabergoline against parkinsonism]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 117, Issue:6 Topics: Animals; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Haplorhini; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine	2001
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17 Suppl 4 Topics: Benzophenones; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Nitrophenols; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Tolcapone	2002
Dopamine agonist monotherapy in Parkinson's disease. Lancet (London, England), 2002, Nov-30, Volume: 360, Issue:9347 Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon	2002
Clinical pharmacokinetics of cabergoline. Clinical pharmacokinetics, 2003, Volume: 42, Issue:7 Topics: Age Factors; Antiparkinson Agents; Cabergoline; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Ergolines; Female; Food-Drug Interactions; Humans; Kidney Diseases; Levodopa; Liver Diseases; Male; Selegiline; Sex Factors	2003
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs & aging, 2003, Volume: 20, Issue:11 Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles	2003
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:5 Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone	2005
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 11 Topics: Apomorphine; Benzophenones; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Ergolines; Humans; Levodopa; Movement Disorders; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone	2005
Dopamine agonists for restless legs syndrome. The Cochrane database of systematic reviews, 2011, Mar-16, Issue:3 Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Levodopa; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Severity of Illness Index	2011
The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep, 2012, Aug-01, Volume: 35, Issue:8 Topics: Academies and Institutes; Benzothiazoles; Cabergoline; Carbamates; Dopamine Agents; Ergolines; Evidence-Based Medicine; gamma-Aminobutyric Acid; Humans; Indoles; Levodopa; Nocturnal Myoclonus Syndrome; Pergolide; Peripheral Nervous System Diseases; Pramipexole; Restless Legs Syndrome; Sleep Medicine Specialty; United States; Venous Insufficiency	2012
Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:7 Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline	2013
Late-onset symptomatic hyperprolactinemia in 6-pyruvoyl-tetrahydropterin synthase deficiency. Orphanet journal of rare diseases, 2023, Nov-10, Volume: 18, Issue:1 Topics: Adolescent; Adult; Cabergoline; Female; Humans; Hyperprolactinemia; Infant, Newborn; Levodopa; Male; Phenylketonurias; Prolactin	2023

Trials

17 trial(s) available for levodopa and cabergoline

Article	Year
Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology, 1993, Volume: 43, Issue:10 Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agents; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine	1993
Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clinical neuropharmacology, 1996, Volume: 19, Issue:3 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease	1996
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology, 1996, Volume: 46, Issue:4 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Patient Dropouts; Placebos; Treatment Outcome	1996
Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. Journal of neurology, 1996, Volume: 243, Issue:1 Topics: Adult; Aged; Blood Pressure; Cabergoline; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Placebos; Severity of Illness Index; Time Factors	1996
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology, 1997, Volume: 48, Issue:2 Topics: Aged; Antiparkinson Agents; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	1997
Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease. Clinical neuropharmacology, 1997, Volume: 20, Issue:5 Topics: Aged; Antiparkinson Agents; Cabergoline; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease	1997
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs, 1998, Volume: 55 Suppl 1 Topics: Activities of Daily Living; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors	1998
Combination of two different dopamine agonists in the management of Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23 Suppl 2 Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome	2002
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs & aging, 2003, Volume: 20, Issue:11 Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles	2003
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS drugs, 2004, Volume: 18, Issue:11 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Risk Factors; Time Factors; Treatment Outcome	2004
Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction (Abingdon, England), 2005, Volume: 100 Suppl 1 Topics: Adult; Cabergoline; Carbidopa; Cocaine-Related Disorders; Dopamine Agents; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Pilot Projects	2005
Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta neurologica Scandinavica, 2006, Volume: 113, Issue:1 Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome	2006
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Movement disorders : official journal of the Movement Disorder Society, 2007, Apr-15, Volume: 22, Issue:5 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ergolines; Europe; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Restless Legs Syndrome	2007
Augmentation in restless legs syndrome is associated with low ferritin. Sleep medicine, 2008, Volume: 9, Issue:5 Topics: Adult; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Ferritins; Humans; Levodopa; Male; Patient Dropouts; Prospective Studies; Restless Legs Syndrome; Retrospective Studies; Risk Factors	2008
Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study. Acta medica Okayama, 2012, Volume: 66, Issue:2 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time; Treatment Outcome	2012
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:3 Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3	2013
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. Neurology, 2013, May-07, Volume: 80, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Corpus Striatum; Dopamine; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Single-Blind Method; Treatment Outcome	2013

Other Studies

40 other study(ies) available for levodopa and cabergoline

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Cabergoline: a long-acting dopamine agonist in Parkinson's disease. Annals of neurology, 1990, Volume: 28, Issue:4 Topics: Administration, Oral; Antiparkinson Agents; Cabergoline; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine	1990
Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile. Annals of neurology, 1995, Volume: 37, Issue:1 Topics: Aged; Bromocriptine; Cabergoline; Chorea; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Parkinson Disease; Pergolide; Sweating	1995
Cabergoline in Parkinson's disease: long-term follow-up. Neurology, 1993, Volume: 43, Issue:12 Topics: Adult; Aged; Cabergoline; Dopamine Agents; Drug Therapy, Combination; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome	1993
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:5 Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E	1995
Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients. Journal of neural transmission. Supplementum, 1995, Volume: 45 Topics: Analysis of Variance; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome	1995
Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents. Biological & pharmaceutical bulletin, 1996, Volume: 19, Issue:11 Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Levodopa; Male; Mice; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reserpine	1996
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys. Journal of neural transmission (Vienna, Austria : 1996), 1996, Volume: 103, Issue:11 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Hyperkinesis; Levodopa; Macaca fascicularis; Movement; Parkinson Disease, Secondary	1996
A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Cabergoline; Disorders of Excessive Somnolence; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies; Thiazoles	2001
Effects of short- and long-acting dopamine agonists on sensitized dopaminergic neurotransmission in rats with unilateral 6-OHDA lesions. Life sciences, 2002, Jan-18, Volume: 70, Issue:9 Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Antagonism; Ergolines; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Synaptic Transmission	2002
Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:5 Topics: Aged; Brain; Cabergoline; Delta Rhythm; Dopamine Agonists; Drug Therapy, Combination; Electroencephalography; Electromyography; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep, REM; Wakefulness	2002
Determination of cabergoline and L-dopa in human plasma using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003, Jul-15, Volume: 792, Issue:1 Topics: Adult; Cabergoline; Case-Control Studies; Chromatography, Liquid; Dopamine Agonists; Ergolines; Humans; Levodopa; Middle Aged; Reproducibility of Results; Schizophrenia; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization	2003
[Three patients with Parkinson's disease whose therapeutic levels were successfully improved after administration of quetiapine for suppression of psychosis]. No to shinkei = Brain and nerve, 2003, Volume: 55, Issue:5 Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cabergoline; Dibenzothiazepines; Ergolines; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Quetiapine Fumarate	2003
Cabergoline versus levodopa monotherapy: a decision analysis. Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:8 Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Making; Disease Progression; Ergolines; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Parkinson Disease; Severity of Illness Index	2003
Improvement of sleep hypopnea by antiparkinsonian drugs in a patient with Parkinson's disease: a polysomnographic study. Internal medicine (Tokyo, Japan), 2003, Volume: 42, Issue:11 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cabergoline; Ergolines; Humans; Levodopa; Male; Parkinson Disease; Polysomnography; Sleep Apnea Syndromes	2003
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:6 Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agonists; Drug Combinations; Echocardiography, Transesophageal; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Levodopa; Male; Parkinson Disease; Pergolide	2004
Cabergoline versus levodopa monotherapy. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:6 Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease	2004
Re: Cabergoline versus levodopa monotherapy: a decision analysis. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:6 Topics: Age Factors; Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Support Techniques; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Surveys and Questionnaires	2004
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:11 Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles	2004
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice. Neuroscience research, 2005, Volume: 51, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cabergoline; Carbidopa; Caspases; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Drug Interactions; Enzyme Activation; Ergolines; Glutathione; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Neurotoxicity Syndromes; Oxidopamine; Thiobarbituric Acid Reactive Substances	2005
Psychiatric sequelae of Parkinson disease: a case report. European psychiatry : the journal of the Association of European Psychiatrists, 2006, Volume: 21, Issue:3 Topics: Antiparkinson Agents; Cabergoline; Carbidopa; Compulsive Behavior; Drug Combinations; Ergolines; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Offenses	2006
Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease. European journal of neurology, 2006, Volume: 13, Issue:4 Topics: Aged; Antiparkinson Agents; Cabergoline; Chromatography, High Pressure Liquid; Ergolines; Female; Free Radical Scavengers; Humans; Levodopa; Male; Oxidative Stress; Parkinson Disease; Peroxynitrous Acid; Tyrosine	2006
Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study. Journal of neural transmission (Vienna, Austria : 1996), 2006, Volume: 113, Issue:12 Topics: Aged; Antiparkinson Agents; Cabergoline; Circadian Rhythm; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep; Wakefulness	2006
[Case of juvenile parkinsonism in pregnancy]. Rinsho shinkeigaku = Clinical neurology, 2006, Volume: 46, Issue:6 Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Contraindications; Dopamine Agents; Dopamine Agonists; Ergolines; Family Planning Services; Female; Humans; Infant, Newborn; Levodopa; Parkinsonian Disorders; Pramipexole; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Thiazoles	2006
[Association between amytrophic lateral sclerosis and Parkinson's disease]. Medicina clinica, 2007, Oct-06, Volume: 129, Issue:12 Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Cabergoline; Carbidopa; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Riluzole; Time Factors; Tomography, X-Ray Computed	2007
Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias. Neuropharmacology, 2008, Volume: 54, Issue:2 Topics: Amino Acids; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Cabergoline; Caudate Nucleus; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; Ergolines; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Ovariectomy; Putamen; Receptors, Metabotropic Glutamate; Xanthenes	2008
Emotional speech in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-30, Volume: 23, Issue:6 Topics: Adult; Aged; Antiparkinson Agents; Articulation Disorders; Cabergoline; Emotions; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Phonation; Speech	2008
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism. Behavioural brain research, 2008, Dec-01, Volume: 194, Issue:1 Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase	2008
Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. Journal of molecular neuroscience : MN, 2009, Volume: 38, Issue:2 Topics: Animals; Autoradiography; Behavior, Animal; Benserazide; Benzoxazoles; Cabergoline; Corpus Striatum; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Ergolines; Female; Humans; Levodopa; Macaca fascicularis; MPTP Poisoning; Ovariectomy; Piperidines; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate	2009
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report. European journal of neurology, 2009, Volume: 16, Issue:2 Topics: Aged; Antiparkinson Agents; Azepines; Benzothiazoles; Cabergoline; Carbidopa; Catatonia; Catechols; Drug Therapy, Combination; Electroconvulsive Therapy; Ergolines; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole	2009
Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity. Journal of neurology, 2009, Volume: 256, Issue:5 Topics: Antiparkinson Agents; Arm; Art; Benzothiazoles; Brain; Cabergoline; Creativity; Depressive Disorder; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Motor Skills; Obsessive Behavior; Paintings; Parkinson Disease; Pramipexole	2009
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys. Progress in neuro-psychopharmacology & biological psychiatry, 2010, Apr-16, Volume: 34, Issue:3 Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Ergolines; Female; Glycogen Synthase Kinase 3; Levodopa; Macaca fascicularis; Oncogene Protein v-akt; Parkinsonian Disorders; Phosphorylation; Piperidines; Serine; Signal Transduction; Statistics as Topic	2010
Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience, 2010, Jun-02, Volume: 167, Issue:4 Topics: Animals; Antiparkinson Agents; Autoradiography; Benzoxazoles; Brain; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Imidazoles; Levodopa; Ligands; Macaca fascicularis; MPTP Poisoning; Piperidines; Quinazolines; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate	2010
Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. The European journal of neuroscience, 2011, Volume: 33, Issue:10 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Biogenic Amines; Brain; Cabergoline; Dopamine Agents; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Ketanserin; Levodopa; Macaca; Parkinsonian Disorders; Receptor, Serotonin, 5-HT2A	2011
Selective IGT decision-making impairment in a patient with juvenile Parkinson's disease and pathological gambling: a role for dopaminergic therapy? Neurocase, 2012, Volume: 18, Issue:6 Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Compulsive Behavior; Decision Making; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Gambling; Humans; Levodopa; Matched-Pair Analysis; Neuropsychological Tests; Parkinsonian Disorders; Pramipexole; Reference Values	2012
Finasteride attenuates pathological gambling in patients with Parkinson disease. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Catechols; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Ergolines; Finasteride; Gambling; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Treatment Outcome; Video Games	2012
'You never told me I would turn into a gambler': a first person account of dopamine agonist--induced gambling addiction in a patient with restless legs syndrome. BMJ case reports, 2011, Aug-24, Volume: 2011 Topics: Cabergoline; Carbidopa; Cognitive Behavioral Therapy; Dopamine Agonists; Drug Combinations; Ergolines; Gambling; Humans; Indoles; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes	2011
Occlusal treatment with bite splint improves dyskinesia in Parkinson's disease patient: a case report. The Bulletin of Tokyo Dental College, 2013, Volume: 54, Issue:3 Topics: Activities of Daily Living; Antiparkinson Agents; Bromocriptine; Cabergoline; Clonidine; Dyskinesias; Ergolines; Female; Hand Strength; Humans; Levodopa; Middle Aged; Motor Skills; Occlusal Splints; Parkinson Disease; Posture	2013
Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010. PloS one, 2014, Volume: 9, Issue:6 Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Prescriptions; Ergolines; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide	2014
Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease. Neuroscience research, 2022, Volume: 178 Topics: Animals; Antiparkinson Agents; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger	2022